Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Investor Presentation (September 2022)
15 slides from Alembic Pharmaceuticals's investor presentation, September 2022
Slide 1: Alembic Pharmaceuticals Limited Investor presentation – September 2022
Alembic Pharmaceuticals Limited Investor presentation – September 2022 BSE & NSE: APLLTD 1
Slide 2: Milestones
Milestones 1907 Established by Amin family 2006 FDA approves API facility 2007 Acquired Dabur’s Indian Cardiology, GI and Gynaecology brands 2008 FDA approves Formulation facility 2009 Multiple divisions to address chronic therapies launched 2010 Pharmaceuticals business demerged from Alembic – APL
Slide 3: Financial Highlights
Financial Highlights INR Bn Particulars Q2 FY23 Q2 FY22 Growth H1 FY23 H1 FY22 Growth FY22 Net Sales 14.75 12.92 14% 27.37 26.18 5% 53.06 EBIDTA Pre R&D 3.73 4.15 -10% 6.15 8.15 -25% 16.40 Margin % 25% 32% 22% 31% 31% R&D 1.68 1.68 0% 4.29 3.35 28% 8.38 R&D % 11% 13% 16% 13% 16% EBIDTA Post R&D 2.31
Slide 4: Revenue snapshot – Q2 & H1 FY23
Revenue snapshot – Q2 & H1 FY23 INR Bn Key Highlights : Business Q1FY23 Q2FY23 Q2FY22 Y-o-Y Q-o-Q H1FY23 H1FY22 Y-0-Y Formulations India Branded Business : India Branded Business recorded India 4.80 5.49 5.09 8% 14% 10.29 9.89 4% 11% growth (Excluding one-time non-recurring sales of US 3.67 4.18 3.4
Slide 5: US Generic
US Generic INR Bn Revenue – Q2 FY23 INR Bn Revenue – Last 5 Years CAGR - 16% 21.63 4.18 19.76 3.48 16.66 12.88 9.20 Q2FY22 Q2FY23 FY18 FY19 FY20 FY21 FY22 Approved ANDAs Injectable Derma 2 Inhalation 24 2 ➢ Well-established US front end having strong customer base ➢ 5 products launched in Q2FY23. Cu
Slide 6: Ex-US Generics
Ex-US Generics Revenue : Q2 FY23 INR Bn Revenue – Last 5 Years INR Bn CAGR - 28% 9% ↑ 2.15 7.79 7.75 1.97 4.94 4.97 Q2FY22 Q2FY23 ➢ The Ex-US business growth of 9% and 18% compared to 2.86 Q2FY23 and Q1FY23, respectively. ➢ Ex-US driven by partnership ➢ Presence in following key markets ➢ - Europe,
Slide 7: API
API Revenue : Q2 FY23 INR Bn Revenue – Last 5 Years INR Bn CAGR - 10% 2.94 9.55 9.39 2.39 7.71 7.08 6.51 Q2FY22 Q2FY23 ➢ Growth of 23% on QoQ basis is mainly on account of high off- take and better product mix in Q2. ➢ API Business posted growth of 26% on Sequential quarter basis. ➢ 1 USDMFs filed i
Slide 8: R&D Significant investments in building capabilities
R&D Significant 10.0 investments in building capabilities INR Bn ANDA – Accelerated filings & approvals 15.8% 37 Filing 8.0 14.0% Approval 13.1% 12.7% 29 30 29 12.4% 6.0 25 R&D Spend 23 20 21 18 19 4.0 8.4 11 Filings & 6.7 7 Approvals 6.5 R&D % of were 5.0 sales 2.0 4.1 contributed by acquisition of
Slide 9: State of the art facilities and infrastructure
State of the art facilities and infrastructure Audit/Filing Location Dosage Form status International Generics F1 – Panelav General Oral Solids Mar’20* Oncology Oral Solids Jun’19* F2 – Panelav Oncology Injectables Oct’22* F2 - Panelav F3 - Karkhadi General Injectables F3 – Karkhadi Ophthalmic Aug’2
Slide 10: Branded Business
Branded Business Revenue – Q2 FY23 INR Bn Revenue – Last 5 Years CAGR - 11% INR Bn 5.49 19.3 *4.96 0.74 0.64 15.0 1.86 13.8 14.3 Vet 1.69 12.7 Acute Speciality 2.88 2.63 Q2FY22 Q2FY23 FY18 FY19 FY20 FY21 FY22 *Excluding one time non recurring sales of Amphotericin-B of Rs 13 Cr in Q2 last year. Mark
Slide 11: Branded Business
Branded Business Top Brands with rank and MS% Prescription Business 622 Leading Brands Other Leading Brands Rank MAT Rank MAT BRANDS MAT Sep SEP 22 BRANDS MAT Sep SEP 22 449 22 MS% 22 MS% AZITHRAL 1 30.7 ELATA 1 41.8 YTD Sep 21 217 TELLZY 5 4.9 VEHYCAL-XT 3 7.1 204 YTD Sep 22 WIKORYL 3 10.2 ESTROPLU
Slide 12: Therapy-wise Performance Q2 FY23
Therapy-wise Performance Q2 FY23 Q2 FY23 Q2 FY22 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy Growth Share % Growth % Growth % Growth Share Growth % Growth % % (IPM) (ORG) (ORG) (PRIM) % (ORG) % (ORG) (ORG) (PRIM) Gynecology 12 2.9 24 27 18 2.6 29 22 Cardiology 10 1.8 7 6 7
Slide 13: Therapy-wise Performance H1 FY23
Therapy-wise Performance H1 FY23 H1 FY23 H1 FY22 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy Growth Share % Growth % Growth % Growth Share Growth % Growth % % (IPM) (ORG) (ORG) (PRIM) % (ORG) % (ORG) (ORG) (PRIM) Gynecology 17 2.9 30 35 21 2.6 34 30 Cardiology 5 1.8 9 8 14
Slide 14: Financials : Generating consistent returns
Financials : Generating consistent returns Revenue INR Bn EBIDTA Net Profit INR Bn INR Bn 53.93 53.06 16.31 11.78 46.06 39.35 12.13 8.29 31.31 10.53 # 8.75 6.65 # 5.84 6.42 4.13 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 CAGR - 14% CAGR - 13% CAGR - 13% EBIDTA margin
Slide 15: Thank you
Thank you Safe Harbour Agreement: Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and resu
Alembic Pharmaceuticals — Investor Presentation (September 2022) on 6ix